Rhythm Lands $11 Million Tranche to Advance Its Treatment of GI Disorders
7/31/2013 8:35:17 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Rhythm Pharmaceuticals, a Boston, Mass. biotech company developing peptide therapeutics, has closed the final tranche of its Series B round of funding. The biotech, which is developing the ghrelin peptide antagonists for the treatment of gastroparesis and other GI disorders as well as for obesity and diabetes, has received an $11 million tranche of its Series B funding, according to documents filed with the U.S. Securities and Exchange Commission on Tuesday.
Help employers find you! Check out all the jobs and post your resume.
comments powered by